Collegium PharmaceuticalCOLL
COLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 357
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
155% more call options, than puts
Call options by funds: $707K | Put options by funds: $277K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
4% less funds holding
Funds holding: 248 [Q3] → 238 (-10) [Q4]
5.17% less ownership
Funds ownership: 120.36% [Q3] → 115.19% (-5.17%) [Q4]
18% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 44
23% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 92
29% less capital invested
Capital invested by funds: $1.5B [Q3] → $1.06B (-$433M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
24%
upside
Avg. target
$44
51%
upside
High target
$50
72%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler David Amsellem 51% 1-year accuracy 18 / 35 met price target | 24%upside $36 | Neutral Maintained | 4 Feb 2025 |
Needham Serge Belanger 45% 1-year accuracy 55 / 123 met price target | 58%upside $46 | Buy Upgraded | 10 Jan 2025 |
HC Wainwright & Co. Oren Livnat 54% 1-year accuracy 26 / 48 met price target | 72%upside $50 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Based on 9 articles about COLL published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025.
Neutral
Seeking Alpha
4 days ago
Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025
Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, previously growing Horizon's revenue from $300 million to $4 billion and selling it to Amgen for $28 billion. The stock is undervalued at 4.5x EBITDA 2024, with potential for re-rating as Jornay PM ramps up and reduces the impact of Nucynta's exclusivity loss.
Neutral
GlobeNewsWire
1 week ago
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare Conference Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit Wednesday, March 12, 2025 Barclays 27 th Annual Global Healthcare Conference Thursday, March 13, 2025 About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
Neutral
Seeking Alpha
1 week ago
Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - President & Chief Executive Officer Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
1 week ago
Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
1 week ago
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.58 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.
Neutral
Zacks Investment Research
2 weeks ago
Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neutral
GlobeNewsWire
4 weeks ago
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
Collegium Provides 2025 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
Charts implemented using Lightweight Charts™